Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation

Rabia Shahswar, MD, Gernot Beutel, MD, Piroska Klement, Alina Rehberg, Razif Gabdoulline, Christian Koenecke, MD, Dominik Markel, MD, Hendrik Eggers, MD, Matthias Eder, MD, Michael Stadler, MD PhD, Lothar Hambach, MD, Steve Ehrlich, MD, Gudrun Gohring, MD, Brigitte Schlegelberger, MD, Arne Trummer, MD, Juergen Krauter, MD, Arnold Ganser, MD, Felicitas Thol, MD, Michael Heuser, MD

Blood (2019) 134 (Supplement_1): 1359.

https://doi.org/10.1182/blood-2019-125377

Published: 2019

Journal Articles

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Blood (2016) 128 (22): 4038.

https://doi.org/10.1182/blood.V128.22.4038.4038

Published: 2016

Journal Articles

Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2015) 126 (23): 912.

https://doi.org/10.1182/blood.V126.23.912.912

Published: 2015

Journal Articles

Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis

Blood (2015) 126 (23): 224.

https://doi.org/10.1182/blood.V126.23.224.224

Published: 2015

Journal Articles

Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG)

Blood (2015) 126 (23): 3818.

https://doi.org/10.1182/blood.V126.23.3818.3818

Published: 2015

Journal Articles

Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML

Felicitas Thol, MD, Aylin Kirchner, Rabia Shahswar, Sofia Kade, Christian Koenecke, MD, Michael Stadler, MD, Uwe Platzbecker, MD, PhD, Christian Thiede, MD, Thomas Schroeder, MD, Guido Kobbe, MD, Gesine Bug, MD, PhD, Oliver G. Ottmann, MD, Wolf-Karsten Hofmann, MD, Nicolaus Kröger, MD, Juergen Krauter, MD, Arnold Ganser, MD, Michael Heuser, MD

Blood (2013) 122 (21): 2804.

https://doi.org/10.1182/blood.V122.21.2804.2804

Published: 2013

Journal Articles

Expression Of Hedgehog Pathway Mediator Gli2 Represents a Clinically Negative Prognostic Marker In Acute Myeloid Leukemia and Its Inhibitor GANT61 Exerts Anti-Leukemic Effects In Vitro

Jasmin Wellbrock, Ph.D., Julian M Koehler, Katharina Wagner, MD, Emily Latuske, M.Sc., Hauke Stamm, M.Sc., Eik Vettorazzi, M.Sc., Gabi Vohwinkel, M.Sc., Marianne Klokow, Roswitha Kuhling-Thees, Sonja Loges, MD, Ph.D, Michael Amling, MD, Carsten Bokemeyer, MD, Michael Heuser, MD, Juergen Krauter, MD, Walter Fiedler, MD

Blood (2013) 122 (21): 53.

https://doi.org/10.1182/blood.V122.21.53.53

Published: 2013

Journal Articles

Prevalence and Clinical Effect of TET2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Birgit Markus, MD, Felicitas Thol, M.D., Michael A Morgan, PhD, Katharina Wagner, MD, Michael Heuser, M.D., Juergen Krauter, MD, Arnold Ganser, MD, Frederik Damm, MD

Blood (2011) 118 (21): 1448.

https://doi.org/10.1182/blood.V118.21.1448.1448

Published: 2011

Journal Articles

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

Blood (2011) 118 (21): 2576.

https://doi.org/10.1182/blood.V118.21.2576.2576

Published: 2011

Journal Articles

Expression of Gli2, a Downstream Mediator of the Activated Hedgehog Pathway, Represents a Negative Prognostic Marker in AML,

Walter Fiedler, M.D., Gabi Vohwinkel, MSc, Juergen Krauter, MD, Eik Vettorazzi, MSc, Sonja Loges, M.D., Ph.D., Livia Fuhrmann, Patrizia Seyfert, Carsten Bokemeyer, M.D., Jasmin Wellbrock, PhD

Blood (2011) 118 (21): 3535.

https://doi.org/10.1182/blood.V118.21.3535.3535

Published: 2011

Journal Articles

Prospective Validation of a Chronic GvHD-Specific Proteome Pattern (cGvHD-MS14) Post Allogeneic Hematopoietic Stem Cell Transplantation

Eva M. Weissinger, MD, Daniel Wolff, Jochen Metzger, Christiane E Dobbelstein, MD, Stefanie Buchholz, MD, Elke Dammann, Uwe Borchert, Annika Krons, Helmut Diedrich, Michael Stadler, MD, Anne M Dickinson, PhD, Ernst Holler, M.D., Hildegard T. Greinix, MD, Juergen Krauter, MD, Arnold Ganser, MD

Blood (2011) 118 (21): 1970.

https://doi.org/10.1182/blood.V118.21.1970.1970

Published: 2011

Journal Articles

Proteomic Pattern-Based Risk Stratification of Outcome Shows Significant Higher Accuracy Compared to HCT-CI in Patients with AML and MDS,

Christiane E Dobbelstein, MD, Jochen Metzger, Elke Dammann, Uwe Borchert, Stefanie Buchholz, MD, Michael Stadler, MD, Matthias Eder, MD, Juergen Krauter, MD, Arnold Ganser, MD, Eva Mischak-Weissinger, MD

Blood (2011) 118 (21): 4128.

https://doi.org/10.1182/blood.V118.21.4128.4128

Published: 2011

Journal Articles

DNMT3A mutations Predict for Inferior Outcome in NPM1 -Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG

Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Peter Paschka, MD, Anja Stölzle, Andrea Corbacioglu, PhD, David Nachbaur, MD, Thomas Kindler, MD, Alexander C. Burchardt, MD, Helmut R. Salih, MD, Hans-Günther Mergenthaler, MD, Hans J. Salwender, MD, Daniela Späth, MSc, Lars Bullinger, Juergen Krauter, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Konstanze Döhner, MD

Blood (2011) 118 (21): 415.

https://doi.org/10.1182/blood.V118.21.415.415

Published: 2011

Journal Articles

Matched Pair Analysis of Cryopreserved Versus Fresh Allogeneic Peripheral Blood Stem Cell Transplantation

Arne Trummer, MD, Juergen Krauter, MD, Michael Stadler, MD, Arnold Ganser, MD, Stefanie Buchholz, MD

Blood (2011) 118 (21): 4529.

https://doi.org/10.1182/blood.V118.21.4529.4529

Published: 2011

Journal Articles

Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia

Marie-Luise Huetter, MD, Walter Fiedler, MD, Andrea Kuendgen, MD, Juergen Krauter, MD, Marie von Lilienfeld-Toal, MD, Sabine Kayser, MD, Heidi Rafler, Hartmut Doehner, MD, Richard F. Schlenk, MD

Blood (2010) 116 (21): 3297.

https://doi.org/10.1182/blood.V116.21.3297.3297

Published: 2010

Journal Articles

Favorable Prognostic Impact of WT1 SNP rs16754 in Cytogenetically Normal AML Independent of MN1, BAALC, and ERG Expression.

Frederik Damm, M.D., Juergen Krauter, Iyas Hamwi, Michael A. Morgan, Ph.D., Gudrun Goehring, Brigitte Schlegelberger, MD, Arnold Ganser, MD, Michael Heuser, MD

Blood (2009) 114 (22): 1622.

https://doi.org/10.1182/blood.V114.22.1622.1622

Published: 2009

Journal Articles

Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Sabine Kayser, Konstanze Doehner, Juergen Krauter, Heinz A. Horst, Marie von Lilienfeld-Toal, Ulrich Germing, Katharina Goetze, Michael Pfreundschuh, Walter Fiedler, MD, Daniela Spaeth, Silja Groner, Brigitte Schlegelberger, Gudrun Goehring, Arnold Ganser, MD, Hartmut Doehner, Richard F. Schlenk

Blood (2009) 114 (22): 2621.

https://doi.org/10.1182/blood.V114.22.2621.2621

Published: 2009

Journal Articles

Long Term Results of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients.

Michael Stadler, MD, Elke Dammann, Stefanie Buchholz, MD, Bernd Hertenstein, MD, Juergen Krauter, MD, Matthias Eder, MD, Arnold Ganser, MD

Blood (2009) 114 (22): 3388.

https://doi.org/10.1182/blood.V114.22.3388.3388

Published: 2009

Journal Articles

Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).

Peter Paschka, M.D., Juan Du, M.D., Richard F. Schlenk, M.D., Lars Bullinger, M.D., Verena I. Gaidzik, M.D., Andrea Corbacioglu, Ph.D., Axel Benner, M.Sc., Manuela Zucknick, Ph.D., Frank Stegelmann, M.D., Daniela Späth, Sabine Kayser, M.D., Brigitte Schlegelberger, MD, Juergen Krauter, M.D., Arnold Ganser, M.D., Hartmut Döhner, Konstanze Döhner

Blood (2009) 114 (22): 825.

https://doi.org/10.1182/blood.V114.22.825.825

Published: 2009

Journal Articles

Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Blood (2009) 114 (22): 578.

https://doi.org/10.1182/blood.V114.22.578.578

Published: 2009

NARROW

Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation

Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis

Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG)

Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML

Expression Of Hedgehog Pathway Mediator Gli2 Represents a Clinically Negative Prognostic Marker In Acute Myeloid Leukemia and Its Inhibitor GANT61 Exerts Anti-Leukemic Effects In Vitro

Prevalence and Clinical Effect of TET2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

Expression of Gli2, a Downstream Mediator of the Activated Hedgehog Pathway, Represents a Negative Prognostic Marker in AML,

Prospective Validation of a Chronic GvHD-Specific Proteome Pattern (cGvHD-MS14) Post Allogeneic Hematopoietic Stem Cell Transplantation

Proteomic Pattern-Based Risk Stratification of Outcome Shows Significant Higher Accuracy Compared to HCT-CI in Patients with AML and MDS,

DNMT3A mutations Predict for Inferior Outcome in NPM1 -Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG

Matched Pair Analysis of Cryopreserved Versus Fresh Allogeneic Peripheral Blood Stem Cell Transplantation

Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia

Favorable Prognostic Impact of WT1 SNP rs16754 in Cytogenetically Normal AML Independent of MN1, BAALC, and ERG Expression.

Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Long Term Results of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients.

Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).

Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only